CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna
VA
22182
United States

Tel: (703) 506-9460

Show jobs for this employer

About CEL-SCI Corporation

CEL-SCI Corporation is a pioneer in cancer immunotherapy. We are a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. CEL-SCI believes that boosting a patient's immune system before surgery, radiation and chemotherapy should provide the greatest possible impact on survival since that is the time when the immune system is the strongest. Therefore, in the Phase 3 clinical study CEL-SCI treated patients who were newly diagnosed with head and neck cancer with Multikine immunotherapy right after diagnosis, BEFORE they went on to receive surgery, radiation and/or chemotherapy. This approach is unique since cancer drugs are mostly given after surgery, radiation and chemotherapy have failed. The Phase 3 study is the largest ever in head and neck cancer with 928 patients enrolled. It reached the targeted threshold required to conduct data evaluation and is currently in the statistical analysis phase. Head and neck cancer represents about 6% of all cancers worldwide and an unmet medical need. Multikine has received Orphan Drug designation from the FDA for this indication. CEL-SCI operates its own 73,000 sq. ft. GMP manufacturing facility that produces Multikine and a separate research & development laboratory that supports the manufacturing of Multikine. CEL-SCI has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Stock Symbol: CVM

Facebook Twitter

CEL-SCI Corporation Overview

452 articles with CEL-SCI Corporation

  • CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of the offering of 1,400,000 shares of its common stock at a price of $22.62 per share, for total gross proceeds of approximately $31.7 million, before deducting underwriting discounts and other offering expenses payable by the Company.

  • CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that, due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm commitment basis 1,400,000 shares of common stock of the Company, at a price to the public of $22.62 per share, representing a 5% discount to the closing price per share.

  • CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results

  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2020, as well as key clinical and corporate developments.

  • CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2020, as well as key clinical and corporate developments. Clinical and Corporate Developments included: During fiscal 2020, the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Injection) conducted an official

  • CEL-SCI Corporation (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13 th Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience. CEL-SCI’s presen

  • CEL-SCI Corporation (NYSE American: CVM ), a Phase 3 cancer immunotherapy company, announced the closing of the offering of 1,000,000 shares of its common stock at a price of $14.65 per share, for total gross proceeds of $14.65 million, before deducting underwriting discounts and other offering expenses payable by the Company. Additionally, the Company has granted the underwriter a 30-day option to purchase up to 150,00

  • CEL-SCI Corporation (NYSE American: CVM) announced today that the Phase 3 study is in the final stage of review which involves statistical analysis of all study data. Data lock has already been completed. Since the required number of events to allow statistical analysis of CEL-SCI’s Phase 3 study in head and neck cancer was reached earlier thi

  • CEL-SCI Corporation (NYSE American: CVM) announced today its LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in stu

  • CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.

  • CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference.

  • CEL-SCI Corporation (NYSE American:CVM) , a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2 nd at 10:20 a.m. ET.

  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2020 and provided an update on clinical developments: CEL-SCI reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its global pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Inj.) immunotherapy. The study is currently in the database l

  • CEL-SCI Corporation (NYSE American: CVM) announces that it has concluded animal experiments using its LEAPS COVID 19 conjugate that provide the basis for moving forward into animal challenge studies with live virus SARS-CoV-2, the causative agent of COVID 19, at the University of Georgia Vaccine Center. These SARS-CoV-2 challenge studies seek to repeat the success of animal challenge studies conducted previously at the NIH

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
  • Portion of funds to be invested in expanding Multikine manufacturing facility in anticipation of marketing approval

  • CEL-SCI Corporation (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:30 p.m. ET. A live audio webcast of the chat will be available at http://wsw.com/webcast/hcw9/cvm or on the Investor Relations section of CEL-SCI’s website

  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2020 and provided an update on clinical developments: On May 4, 2020, CEL-SCI announced it has been notified that it reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its pivotal Phase 3 head

  • It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
  • CEL-SCI Corporation announced that it has been notified that it has reached the targeted threshold of 298 events required to conduct the data evaluation for its pivotal Phase 3 head and neck cancer study of Multikine* immunotherapy.